Keywords
How to Cite
Abstract
Uveal melanoma is a big challenge for medicine, because despite successful local treatment, metastatic disease develops frequently and this is an important factor affecting patient survival. Revealing mechanisms of pathogenesis of this disease and developing targeted therapy requires high-quality animal models that reproduce many aspects of tumor biology, mimic its metastasis dissemination and, most importantly, can be the basis for understanding the principles of diagnosis and treatment. Methods for creating a model of uveal melanoma include injecting syngeneic skin melanoma cells to the experimental animals, injecting xenogenic uveal and skin melanoma cells that can be of both human and animal origin, as well as transplanting xenografts obtained from patients and creating transgenic and induced tumor models. In this review, we analyzed the data of the last 30 years on the methods of modeling uveal melanoma, described the advantages, disadvantages and features that must be considered.References
Кит О.И., Колесников Е.Н., Максимов А.Ю., Протасова Т.П., Гончарова А.С., Лукбанова Е.А. Методы создания ортотопических моделей рака пищевода и их применение в доклинических исследованиях // Современные проблемы науки и образования. - 2019. - №2.
Козина Елена Владимировна, Козина Юлия Валерьевна, Гололобов Владимир Трофимович, Кох Ирина Андреевна Увеальная меланома: основные эпидемиологические аспекты и факторы риска // Сибирское медицинское обозрение. 2014. №4 (88).
Назарова В.В., Орлова К.В., Утяшев И.А., Мазуренко H. Н., Демидов Л.В. Современные тенденции в терапии увеальной меланомы: обзор проблемы // Злокачественные опухоли. - 2014. - № 4.
Саакян С. В., Ширина Т В. Анализ метастазирования и выживаемости больных увеальной меланомой // Опухоли головы и шеи. - 2012. - №2.
Яровая В.А., Яровой А.А., Зарецкий А.Р и др. Молекулярно-генетический анализ увеальной меланомы при органосохраняющем лечении // ПМ. - 2018. - №3 (114).
Albert D.M. et al. Feline uveal melanoma model induced with feline sarcoma virus //Investigative ophthalmology
Amaro A. et al. The biology of uveal melanoma // Cancer and Metastasis Reviews. - 2017. - Vol. 36. - №. 1. - P 109-140.
Angi M., Versluis M., Kalirai H. Culturing uveal melanoma cells // Ocular oncology and pathology. - 2015. - Vol. I. - №. 3. - P. 126-132.
Brown K. M. et al. Patient-derived xenograft models of colorectal cancer in pre-clinical research: a systematic review //Oncotarget. - 2016. - Vol. 7. - №. 40. - P 66212.
Braun R. D., Vistisen K. S. Modeling human choroidal melanoma xenograft growth in immunocompromised rodents to assess treatment efficacy //Investigative ophthalmology
Cao J., Jager M. J. Animal eye models for uveal melanoma //Ocular oncology and pathology. - 2015. - Vol. 1. - №. 3. - P. 141-150.
Cassidy J. W. et al. Patient-derived tumour xenografts for breast cancer drug discovery //Endocrine-related cancer. - 2016. - Vol. 23. - №. 12. - P T259-T270.
Chang A. E., Karnell L. H., Menck H. R. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade //Cancer: Interdisciplinary International Journal of the American Cancer Society. - 1998. - Vol. 83. - №. 8. - P 1664-1678.
Davidson H. J. et al. Anterior uveal melanoma, with secondary keratitis, cataract, and glaucoma, in a horse //Journal of the American Veterinary Medical Association. - 1991. - Vol. 199. - №. 8. - P 1049-1050.
De Lange J. et al. Synergistic growth inhibition based on small-molecule p53 activation as treatment for intraocular melanoma //Oncogene. - 2012. - Vol. 31. - №. 9. - P 1105.
Diaz C. E. et al. B16LS9 melanoma cells spread to the liver from the murine ocular posterior compartment (PC) //Current eye research. - 1999. - Vol. 18. - №. 2. - P 125-129.
Egan K. M. et al. Epidemiologic aspects of uveal melanoma //Survey of ophthalmology. - 1988. - Vol. 32. - №. 4. - P 239-251.
Fidler I. J., Nicolson G.L. Organ selectivity for implantation survival and growth of B16 melanoma variant tumor lines // Journal of the National Cancer Institute. - 1976. - Vol. 57. - №. 5. - P. 1199-1202.
Gonzalez V.H. et al. Photodynamic therapy of pigmented choroidal melanomas // Investigative ophthalmology
Gould S. E., Junttila M. R., de Sauvage F. J. Translational value of mouse models in oncology drug development // Nature medicine. - 2015. - Vol. 21. - №. 5. - P 431.
Grossniklaus H.E., Barron B.C., Wilson M.W. Murine model of anterior and posterior ocular melanoma // Current eye research. - 1995. - Vol. 14. - №. 5. - P 399-404.
Hanahan D., Weinberg R. A. Hallmarks of cancer: the next generation // Cell. - 2011. - Vol. 144. - №. 5. - P 646-674.
Hidalgo M. et al. Patient-derived xenograft models: an emerging platform for translational cancer research // Cancer discovery. - 2014. - Vol. 4. - №. 9. - P 9981013.
Huang J. L. Y, Urtatiz O., Van Raamsdonk C. D. Oncogenic G protein GNAQ induces uveal melanoma and intravasation in mice // Cancer research. - 2015. - С. canres. 3229.2014.
Kan-Mitchell J. et al. Characterization of uveal melanoma cell lines that grow as xenografts in rabbit eyes // Investigative ophthalmology
Shikishima K. Methods for subchoroidal implantation of Greene melanoma in rabbits //International journal of clinical oncology. - 2004. - Vol. 9. - №. 2. - P 79-84.
Singh A. D. et al. Lifetime prevalence of uveal melanoma in white patients with oculo (dermal) melanocytosis // Ophthalmology. - 1998. - Vol. 105. - №. 1. - P 195-198.
Spaw M., Anant S., Thomas S. M. Stromal contributions to the carcinogenic process // Molecular carcinogenesis. - 2017. - Vol. 56. - №. 4. - P 1199-1213.
Stei M. M. et al. Animal models of uveal melanoma: methods, applicability, and limitations // BioMed research international. - 2016. - Vol. 2016.
Ssskind D. et al. Novel mouse model for primary uveal melanoma: a pilot study // Clinical
Triozzi P L., Aldrich W., Singh A. Effects of interleukin-1 receptor antagonist on tumor stroma in experimental uveal melanoma // Investigative ophthalmology
Van der Ent W. et al. Modeling of human uveal melanoma in zebrafish xenograft embryos // Investigative ophthalmology
Van Raamsdonk C.D. et al. Mutations in GNA11 in uveal melanoma // New England Journal of Medicine. - 2010. - Vol. 363. - №. 23. - P. 2191-2199.
Virgili G. et al. Incidence of uveal melanoma in Europe // Ophthalmology. - 2007. - Vol. 114. - № 12. - P 23092315. e2.
Wang S. et al. Effect of an anti-CD54 (ICAM-1) monoclonal antibody (UV3) on the growth of human uveal melanoma cells transplanted heterotopically and orthotopically in SCID mice // International journal of cancer. - 2006. -Vol. 118. - № 4. - P 932-941.
Weis E. et al. The association between host susceptibility factors and uveal melanoma: a meta-analysis // Archives of ophthalmology. - 2006. - Vol. 124. - №.1. - P 54-60.
Wilcock B. P, Peiffer Jr R. L. Morphology and behavior of primary ocular melanomas in 91 dogs // Veterinary Pathology. - 1986. - Vol. 23. - №. 4. - P 418-424.
Yang H. et al. In-vivo xenograft murine human uveal melanoma model develops hepatic micrometastases // Melanoma research. - 2008. - Vol. 18. - №. 2. - P 95.
Yang H. et al. The Toll-like receptor 5 agonist entolimod suppresses hepatic metastases in a murine model of ocular melanoma via an NK cell-dependent mechanism // Oncotarget. - 2016. - Vol. 7. - № 3. - P 2936.
Yang H., Cao J., Grossniklaus H. E. Uveal melanoma metastasis models // Ocular oncology and pathology. -2015. - Vol. 1. - № 3. - P 151-160.
Yang H., Jager M. J., Grossniklaus H. E. Bevacizumab suppression of establishment of micrometastases in experimental ocular melanoma // Investigative ophthalmology
Shain A. H., Bastian B. C. From melanocytes to melanomas //Nature reviews cancer. - 2016. - Vol. 16. - №. 6. - P 345
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2019